Literature DB >> 25179737

Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health.

Brendan Saloner1, Meredith Matone, Amanda R Kreider, M Samer Budeir, Dorothy Miller, Yuan-Shung Huang, Ramesh Raghavan, Benjamin French, David Rubin.   

Abstract

OBJECTIVE: Reducing overuse of second-generation antipsychotics among Medicaid-enrolled children is a national priority, yet little is known about how service organization affects use. This study compared differences in second-generation antipsychotic utilization among Medicaid-enrolled children across fee-for-service, integrated managed care, and managed behavioral health carve-out organizational structures.
METHODS: Organizational structures of Medicaid programs in 82 diverse counties in 34 states were categorized and linked to child-level cross-sectional claims data from the Medicaid Analytic Extract covering fiscal years 2004, 2006, and 2008. To approximate the population at risk of antipsychotic treatment, the sample was restricted to stimulant-using children ages three to 18 (N=419,226). The sample was stratified by Medicaid eligibility group, and logistic regression models were estimated for probability of second-generation antipsychotic use. Models included indicators of county-level organizational structure as main predictors, with sequential adjustment for personal and county-level covariates.
RESULTS: With adjustment for person-level covariates, second-generation antipsychotic use was 31% higher among youths in foster care in fee-for-service counties than for youths in counties with carve-outs (odds ratio [OR]=1.69, 95% confidence interval [CI]=1.26-2.27). Foster care youths in integrated counties had the second highest adjusted odds (OR=1.31, CI=1.08-1.58). Similar patterns of use also were found for youths eligible for Supplemental Security Income but not for those eligible for Temporary Assistance for Needy Families. Differences persisted after adjustment for county-level characteristics.
CONCLUSIONS: Carve-outs, versus other arrangements, were associated with lower second-generation antipsychotic use. Future research should explore carve-out features (for example, tighter management of inpatient or restricted access, as well as care coordination) contributing to lower second-generation antipsychotic use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25179737      PMCID: PMC4757898          DOI: 10.1176/appi.ps.201300574

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  28 in total

1.  Managing behavioral health in Medicaid.

Authors:  David Mechanic
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

2.  Use of antipsychotic medications in treating schizophrenia among different financing and delivery systems.

Authors:  Joan R Bloom; Jur-Shan Cheng; Teh-wei Hu; Soo Hyang Kang; Neal Wallace
Journal:  J Ment Health Policy Econ       Date:  2003-12

3.  County-level estimates of need for mental health professionals in the United States.

Authors:  Thomas R Konrad; Alan R Ellis; Kathleen C Thomas; Charles E Holzer; Joseph P Morrissey
Journal:  Psychiatr Serv       Date:  2009-10       Impact factor: 3.084

4.  Antipsychotic medication use among children and risk of diabetes mellitus.

Authors:  Susan E Andrade; Joan C Lo; Douglas Roblin; Hassan Fouayzi; Daniel F Connor; Robert B Penfold; Malini Chandra; George Reed; Jerry H Gurwitz
Journal:  Pediatrics       Date:  2011-11-21       Impact factor: 7.124

5.  Investigating geographic variation in use of psychotropic medications among youth in child welfare.

Authors:  Laurel K Leslie; Ramesh Raghavan; Maia Hurley; Jinjin Zhang; John Landsverk; Gregory Aarons
Journal:  Child Abuse Negl       Date:  2011-05

6.  Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications.

Authors:  Tim A Bruckner; Ashley Hodgson; Chris Brown Mahoney; Brent D Fulton; Peter Levine; Richard M Scheffler
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-10-24       Impact factor: 2.890

7.  Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

Authors:  Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

Review 8.  Achieving better health care outcomes for children in foster care.

Authors:  Robin Mekonnen; Kathleen Noonan; David Rubin
Journal:  Pediatr Clin North Am       Date:  2009-04       Impact factor: 3.278

9.  Increasing California children's Medicaid-financed mental health treatment by vigorously implementing Medicaid's Early Periodic Screening, Diagnosis, and Treatment (EPSDT) Program.

Authors:  Lonnie R Snowden; Mary Masland; Neal Wallace; Kya Fawley-King; Alison Evans Cuellar
Journal:  Med Care       Date:  2008-06       Impact factor: 2.983

10.  Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample.

Authors:  Emily R Cox; Brenda R Motheral; Rochelle R Henderson; Doug Mager
Journal:  Pediatrics       Date:  2003-02       Impact factor: 7.124

View more
  3 in total

1.  Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study.

Authors:  Hankil Lee; Dong-Ho Song; Jin-Won Kwon; Euna Han; Min-Jung Chang; Hye-Young Kang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-19       Impact factor: 4.785

2.  Prior Authorization Policies and Preferred Drug Lists in Medicaid Plans: Stakeholder Perspectives on the Implications for Youth with ADHD.

Authors:  Sarah C Blake; Minna Song; Laura Gaydos; Janet R Cummings
Journal:  Adm Policy Ment Health       Date:  2019-09

3.  Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018.

Authors:  Molly Candon; Siyuan Shen; Oluwatoyin Fadeyibi; Joseph L Smith; Aileen Rothbard
Journal:  BMC Psychiatry       Date:  2021-10-22       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.